3results about How to "Dose-dependent improvement" patented technology

The present application relates to the technical field of medicine, in particular to the application of gushangamine alcohol in treating pain. The present application first discovers that gushangamine alcohol has significant analgesic activity through pharmacodynamics experiment. In the hot plate method and acetic acid writhing method mouse pain model, gushangamine alcohol shows good analgesic effect, and the analgesic effect is better than that of gushangmethyl, gushangheptane and gushangnonose, etc. C 20 type diterpene alkaloid in the same class of gushangbai, and has good dose dependence, and can be used for treating various painful diseases such as acute pain, chronic pain, inflammatory pain, neuropathic pain, cancer pain, postoperative pain and traumatic pain, and has good drug development and clinical application prospect.

The invention relates to a traditional Chinese medicine composition with an effect of reducing uric acid as well as a preparation method and application of the traditional Chinese medicine composition, which can effectively solve the problems of large toxic and side effects, poor safety after long-term use and low patient tolerance of the existing uric acid reducing medicine. The compound traditional Chinese medicine is prepared from the following raw material medicines in parts by weight: 1 to 20 parts of flos chrysanthemi, 1 to 10 parts of radix puerariae, 1 to 8 parts of folium mori, 1 to 8 parts of herba taraxaci, 1 to 10 parts of herba cichorii, 1 to 5 parts of herba pogostemonis, 1 to 5 parts of bulbus lilii, 1 to 5 parts of orange peel, 0.1 to 2 parts of radix ginseng and 0.1 to 2 parts of cordyceps militaris peptide. The effects of remarkably reducing the serum uric acid level, regulating the URAT1 protein expression of the kidney and reducing uric acid reabsorption are achieved, so that the hyperuricemia and related complications thereof are effectively prevented and treated.

This invention relates to the application of (E)-2-(4-(dimethylamino)styryl)-6-methoxy-3-methylbenzo[d]thiazol-3-onthium in the preparation of anticancer drugs, belonging to the field of pharmaceutical technology. The structure of (E)-2-(4-(dimethylamino)styryl)-6-methoxy-3-methylbenzo[d]thiazol-3-onthium is shown in Formula I below. The (E)-2-(4-(dimethylamino)styryl)-6-methoxy-3-methylbenzo[d]thiazol-3-onthium of this invention can inhibit the growth of gastric cancer cells. By promoting autophagy and mitochondrial fragmentation in gastric cancer cells AGS and HGC-27, it inhibits the proliferation, invasion, and migration of gastric cancer cells and arrests them in the G1 phase. Furthermore, in vivo experiments in mice have confirmed that ZWK-3 can inhibit tumor growth in mice in a significant dose-dependent manner, without affecting mouse body weight or visceral indices. Formula I.